The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer

Abstract

On a global scale, pancreatic cancer is a leading cause of cancer-related death. According to the GLOBOCAN data, approximately half a million people were diagnosed and died from pancreatic cancer in 2018. 1 The most prevalent histological subtype of pancreatic cancer is adenocarcinoma, with the cancer of the pancreatic head accounting for a majority of cases (60-70%). At the time of diagnosis, approxi-mately 80-85% of individuals with pancreatic adenocarcinoma are ineligible for curative treatment. 2 Survival and response rates to treatment remain low due to the unique pathological features of pancreatic adenocarcinoma. Targeted therapies and immune checkpoint inhibitors that have shown efficacy in other types of cancer have not been significantly beneficial in advanced pancreatic cancer, except in indi-69 69 69